drugset / Trial / NCT05303064

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT05303064

Phase 3 Recruiting 220 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

Timeline

Start
2022-06-30
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olanzapine Small molecule 2.5 mg
Comparator Olanzapine Small molecule 5 mg
Comparator Olanzapine Small molecule 20 mg
Subject Samidorphan Small molecule 5 mg
Subject Samidorphan Small molecule 10 mg